Raoul de Navery

Naveris Receives Medicare Coverage for NavDx® Test

Retrieved on: 
Thursday, November 30, 2023
Oncology, Medical Supplies, Health, Health Technology, Health Insurance, Biotechnology, Palmetto, DNA, Head, TTMV, Patient, MRD, MD, Diagnosis, Medicare, Doctor of Philosophy, Cancer, Recurrence, Physician, Raoul de Navery

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular Diagnostics Services program (MolDX®), established Medicare coverage for NavDx®, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular Diagnostics Services program (MolDX®), established Medicare coverage for NavDx®, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA.
  • NavDx is the first and only clinically validated circulating TTMV-HPV DNA blood test.
  • “This decision underscores the powerful clinical utility of Naveris’ TTMV platform and comes at a time of significant company momentum,” said James McNally, Chief Executive Officer of Naveris.
  • “Medicare coverage and future reimbursement will increase patient access to NavDx and we look forward to continued access expansion through commercial channels in the near future.”

Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Other Health, Health, General Health, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, TTMV, Abstract, DNA, Session, San Diego Convention Center, Head, ASTRO, OPSCC, Booth, Cancer, American Academy of Otolaryngology–Head and Neck Surgery, American Academy, Radiation therapy, American Society for Radiation Oncology, MRD, MD, Annual general meeting, HPV, AM, Neoplasm, Recurrence, Society, Neck, Vaccine, Raoul de Navery

Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA.

Key Points: 
  • Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA.
  • The company will also highlight its TTMV-DNA platform in abstracts selected for oral presentation at both meetings.
  • “There is growing enthusiasm for the use of NavDx in daily practice across the continuum of HPV-driven OPSCC care, especially in the surveillance setting,” said Barry M. Berger, MD, Chief Medical Officer of Naveris.
  • Naveris and NavDx will be on exhibit at AAO-HNSF 2023 at Booth #608 and at ASTRO 2023 at Booth #3325.

ACS BrightEdge Poised to Help Improve 1.5 Million Lives By Investing in Cancer-Focused Therapies and Technologies

Retrieved on: 
Wednesday, August 16, 2023
Arm, Therapy, Health, Health equity, Bone marrow, Cancer, Estate (law), Patient, ACS, Annual report, Investment, Vincere, Diagnosis, American Cancer Society, Pharmaceutical industry, Paradigm, Raoul de Navery

BOSTON, Aug. 16, 2023 /PRNewswire/ -- BrightEdge LLC, the American Cancer Society's (ACS) venture capital and impact investment arm, published its most recent annual report, featuring how its portfolio of 18 companies has the potential to improve the lives of more than 1.5 million cancer patients and their families. BrightEdge's estimate is based on its proprietary Cancer Impact Investing Framework™ (CIIF), which evaluates and measures the actual and potential impact of investments made in accordance with the ACS mission-driven priorities.

Key Points: 
  • Using CIIF, BrightEdge invested in four new companies in 2022: CellCentric, Paradigm, Vincere Health and Naveris.
  • Across its 18 portfolio companies, BrightEdge has invested $28.9M to date from the donor-funded ACS Impact Venture Fund (AIVF).
  • "BrightEdge works alongside ACS to not only accelerate patient-centric therapies and technologies but also provide alternative funding for our vision," said Dr. Karen E. Knudsen , CEO of the American Cancer Society.
  • Like traditional venture capital, BrightEdge invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, devices and technologies.

Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial

Retrieved on: 
Wednesday, April 12, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, TTMV, Mayo Clinic, College, Progression-free survival, ASTRO, Clinical trial, Cancer, Head, College of American Pathologists, MRD, DART, CLIA, Patient, Physician, Risk, Disease, Recurrence, III, Vaccine, Pharmaceutical industry, Raoul de Navery

Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic.

Key Points: 
  • Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic.
  • The DART 2.0 trial will evaluate the ability of NavDx, Naveris’ flagship blood test for tumor tissue modified viral (TTMV)-HPV DNA, to improve treatment selection in patients with HPV-driven head and neck cancer.
  • "This clinical trial represents a significant step forward in personalized medicine for head and neck cancer patients," said Piyush B. Gupta PhD, Founder and CEO of Naveris.
  • DART 2.0 builds upon the results of the previously reported phase III MC1675 DART clinical trial, where NavDx-detected molecular residual disease (MRD) was a significant risk factor for cancer recurrence in patients with head and neck cancer.

Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Oncology, LinkedIn, Papilloma, CLIA, College of American Pathologists, Risk, Mayo Clinic, Disease, American Society for Radiation Oncology, Head, Radiation, DART, TTMV, List of pathologists, Society, Patient, Biotechnology, Twitter, Annual general meeting, Cancer, III, DRS, MRD, Radiation therapy, ASTRO, Progression-free survival, Toxicity, CEO, College, Recurrence, HPV, OPSCC, DNA, Medical imaging, Pharmaceutical industry, Vaccine, Raoul de Navery

radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.

Key Points: 
  • radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.
  • The presence of MRD, both in the post-operative setting and at 3 months post-treatment, was significantly associated with shorter progression-free survival.
  • Results from the MC1675 trial were initially presented at the ASTRO 2021 annual meeting and follow-up is ongoing.
  • More information on Naveris and NavDx can be found at booth #2348, or look for highlights from #ASTRO22 Twitter and LinkedIn .

Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx

Retrieved on: 
Monday, September 19, 2022
Infectious Diseases, Genetics, Clinical Trials, Cardiology, Stem Cells, Other Health, Biotechnology, General Health, Health, Oncology, American Cancer Society, Rest, Risk, College of American Pathologists, Health, Industry, Infection, Patient, Cancer, Technology, College, CLIA, HPV, Research, Biotechnology, DNA, List of pathologists, Pharmaceutical industry, Vaccine, Medical imaging, Raoul de Navery

Naveris blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.

Key Points: 
  • Naveris blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.
  • Proceeds from this financing will be used to advance commercialization of NavDx, Naveris flagship blood test for the early detection of cancers caused by the human papillomavirus (HPV), and to generate the clinical data needed to expand into other cancer types and indications.
  • We founded Naveris on the belief that advances in molecular diagnostics will play a vital role in improving cancer outcomes.
  • Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution.

Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 3, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Head, EDT, Physical Sciences-Oncology Centers, Society, Plasma, ASCO, TTMV, IMRT, Annual general meeting, Cisplatin, Physician, American Society of Clinical Oncology, Patient, Risk, Head and neck cancer, HPV, Association, Vaccine, Medical imaging, Raoul de Navery

Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.

Key Points: 
  • Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.
  • Results of TTMV-HPV DNA testing in the NRG-HN002 phase II clinical trial for patients with p16-positive oropharynx cancer treated with intensity-modulated radiation therapy (IMRT), with or without cisplatin chemotherapy, will be shared in the presentation.
  • The company applies its innovative and patented technology to develop molecular diagnostics which enable earlier detection of viral cancers.
  • Naveris' first commercial-stage diagnostic, NavDx, is a blood test that supports the clinical management of patients with HPV-driven cancers.

Sprinter Health and Naveris Partner to Expand Access to NavDx® Cancer Blood Test

Retrieved on: 
Thursday, February 3, 2022
Technology, Mobile, Wireless, Nursing, Software, Internet, Managed Care, Health, General Health, Oncology, Online, CEO, DNA, HPV, Risk, Patient, CT, Health, Physician, Physical Sciences-Oncology Centers, Oropharyngeal cancer, Fasting, Twitter, Technology, COVID-19, TTMV, COVID-19 testing, Cancer, Recurrence, Partnership, PET, BS, Head, Sprinter, LinkedIn, Pharmaceutical industry, Medical imaging, Vaccine, Raoul de Navery, Sprinter Health, Naveris, Inc., SPRINTER HEALTH, NAVERIS, INC.

Patients living in Sprinter Health service areas will be able to easily schedule a visit from a Sprinter Health nurse or phlebotomist (also known as Sprinters) to collect blood specimens for the test in the comfort of their homes.

Key Points: 
  • Patients living in Sprinter Health service areas will be able to easily schedule a visit from a Sprinter Health nurse or phlebotomist (also known as Sprinters) to collect blood specimens for the test in the comfort of their homes.
  • The NavDx blood test uses proprietary technology to detect circulating tumor tissue modified HPV (TTMV) DNA.
  • Were proud to play a small part in helping patients access Naveris innovative test, and look forward to expanding our partnership throughout 2022.
  • Naveris' flagship diagnostic, NavDx, is a blood test that supports the clinical management of patients with HPV-driven cancers.